Collaboration: central to our success
Our purpose is to push the boundaries of science to deliver life-changing medicines. We can’t do this alone, so our way of working is inclusive, open and collaborative. We aim to create mutually beneficial partnerships founded on trust and transparency.
Who we partner with
We partner with academia, governments, peer companies, biotechs, scientific organisations and patient groups to access the best science, stimulate innovation and accelerate delivery of new medicines to target unmet medical need.
From pre-clinical through to commercialisation
From pre-clinical research collaborations through to late-stage development and commercialisation, we’re looking for partners with cutting-edge technologies that can help enhance the quality, effectiveness and productivity of our research and translational capabilities across our main therapy areas. Our areas of interest also include precision medicine and genomics, artificial intelligence and digital capabilities.
Our business development activity takes many forms
Collaborations, in-licensing and acquisitions
with peer companies, biotechs and academia to enhance our portfolio and pipeline in our main therapy areas.
Out-licensing and divestment of medicines
that sit outside our main therapy areas and mature brands that can be deployed better by a partner. This allows us to maximise the value of our assets while ensuring patients have access to these medicines.
sharpen our focus on developing key assets within our main therapy areas by helping us access external therapy area expertise and increasing the reach of medicines in which we maintain an ongoing interest outside our main therapy areas.
Precision medicine collaborations
to help target our innovative medicines to those patients most likely to benefit.
Joint research centres
with leading academic institutes across the globe.
CoSolve Open Innovation Challenge
Sharing real challenges facing our drug discovery and development teams today. We want to find bold innovators, particularly from start-ups and early-stage biotechs, to work with us to help solve them.
How we evaluate potential collaborations
We assess all projects against our ‘5Rs’ framework to ensure we take forward the most attractive opportunities, regardless of source. This also enables us to provide consistent, objective feedback to potential partners.
We are committed to creating strong, long-term partnerships that help speed the delivery of innovative and life-changing medicines to the people who need them. We also work hard to ensure that both parties receive the greatest possible value from the relationship.
Our Alliance & Integration Management team is engaged throughout the deal process. Gaining an early understanding of the strategic, operational and cultural fit between us and our partners helps us structure the partnership governance to be as effective as possible from the start. It also helps to build trust, transparency and strong relationships at all levels.
Our Alliance & Integration Management team members are highly experienced professionals with different backgrounds, which enables us to bring the optimal skill-set to any collaboration. A dedicated member of our Alliance & Integration Management team is assigned during the evaluation stage and remains your key contact throughout the collaboration.
Based on our work across a wide range of complex business and scientific collaborations, we have developed industry-leading processes and tools that ensure smooth and efficient interactions.
In acquisitions, divestments and spinoffs, our Alliance & Integration Management team acts as the central hub for key functional areas across the business, ensuring an efficient integration or transition of the products involved.
Veeva ID: Z4-27153
Date of Prep: Sept 2020